Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6.9% – What’s Next?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)’s share price traded down 6.9% on Wednesday . The stock traded as low as $21.33 and last traded at $21.5140. 596,817 shares were traded during trading, a decline of 79% from the average session volume of 2,820,841 shares. The stock had previously closed at $23.10.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GLUE shares. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 target price (up previously from $27.50) on shares of Monte Rosa Therapeutics in a report on Wednesday, January 14th. Zacks Research upgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $31.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. TD Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $37.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.33.

Monte Rosa Therapeutics Stock Performance

The stock has a market cap of $1.34 billion, a PE ratio of 64.13 and a beta of 1.60. The company has a 50 day moving average of $18.89 and a two-hundred day moving average of $11.63.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.06. The business had revenue of $12.77 million during the quarter, compared to the consensus estimate of $7.37 million. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%. As a group, equities research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total value of $128,396.34. Following the transaction, the chief executive officer owned 618,937 shares in the company, valued at approximately $14,538,830.13. This trade represents a 0.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of hedge funds have recently modified their holdings of GLUE. Vanguard Group Inc. lifted its stake in shares of Monte Rosa Therapeutics by 8.6% in the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after buying an additional 257,547 shares in the last quarter. AQR Capital Management LLC lifted its stake in Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after purchasing an additional 1,054,406 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Monte Rosa Therapeutics by 12.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock worth $5,071,000 after purchasing an additional 120,098 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Monte Rosa Therapeutics by 102.4% during the 3rd quarter. Marshall Wace LLP now owns 902,834 shares of the company’s stock worth $6,690,000 after purchasing an additional 456,754 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new stake in shares of Monte Rosa Therapeutics in the third quarter valued at approximately $5,928,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.